Drug intelligence / Profile preview

VTA-400

Development stage: Preclinical
Lead developer: Vita Therapeutics
Modality: AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

VTA-400 is an investigational gene therapy developed by Vita Therapeutics. It utilizes exosomes and adeno-associated virus (AAV) vectors as its delivery modalities. The therapy is being explored primarily for the treatment of facioscapulohumeral muscular dystrophy, a form of muscular dystrophy affecting the muscles of the face, shoulder blades, and upper arms. The drug is in preclinical development and targets diseases within the nervous system, congenital disorders, as well as skin and musculoskeletal diseases[1][2]. Specific molecular targets or mechanisms have not been publicly disclosed.

Beyond the preview

Go deeper on VTA-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VTA-400.

Explore the full profile